Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts.

During the past decade, Massachusetts General Hospital, Dana-Farber Cancer Institute conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 10 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Massachusetts General Hospital, Dana-Farber Cancer Institute" #1 sponsor was "Celgene" with 7 trials, followed by "Medical College of Wisconsin" with 7 trials sponsored, "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials sponsored, "CTI BioPharma" with 1 trials sponsored and "Eisai Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Massachusetts General Hospital, Dana-Farber Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 10 trials as a collaborator, "Blood and Marrow Transplant Clinical Trials Network" with 9 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 8 trials as a collaborator, "National Marrow Donor Program" with 6 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Massachusetts General Hospital, Dana-Farber Cancer Institute" are "Acute Leukemia" (3 trials), "Leukemia, Myeloid, Acute" (3 trials), "Lymphoma, B-Cell" (3 trials), "Lymphoma, Follicular" (3 trials) and "Lymphoma, Large B-Cell, Diffuse" (3 trials). Many other conditions were trialed in "Massachusetts General Hospital, Dana-Farber Cancer Institute" in a lesser frequency.

Most popular intervention types in "Massachusetts General Hospital, Dana-Farber Cancer Institute" are "Drug" (19 trials), "Procedure" (5 trials), "Biological" (3 trials), "Genetic" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (4 trials), "Methotrexate" (3 trials), "Tacrolimus" (3 trials), "CC-93538" (2 trials) and "Fludarabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Massachusetts General Hospital, Dana-Farber Cancer Institute" are 24 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Massachusetts General Hospital, Dana-Farber Cancer Institute". undefined are not yet recruiting, 6 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Massachusetts General Hospital, Dana-Farber Cancer Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Massachusetts General Hospital, Dana-Farber Cancer Institute, 6 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".